StrykerSYK
SYK
About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
Employees: 53,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
72% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 93
70% more call options, than puts
Call options by funds: $613M | Put options by funds: $360M
28% more repeat investments, than reductions
Existing positions increased: 926 | Existing positions reduced: 725
10% more funds holding in top 10
Funds holding in top 10: 73 [Q4 2024] → 80 (+7) [Q1 2025]
1% more funds holding
Funds holding: 2,149 [Q4 2024] → 2,171 (+22) [Q1 2025]
2% more capital invested
Capital invested by funds: $108B [Q4 2024] → $110B (+$2.43B) [Q1 2025]
0.25% less ownership
Funds ownership: 77.85% [Q4 2024] → 77.6% (-0.25%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$390
3%
upside
Avg. target
$429
14%
upside
High target
$456
21%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Citigroup Joanne Wuensch | 21%upside $455 | Buy Maintained | 22 May 2025 |
Truist Securities Richard Newitter | 6%upside $400 | Hold Maintained | 5 May 2025 |
Roth MKM Jason Wittes | 21%upside $456 | Buy Maintained | 2 May 2025 |
Evercore ISI Group Vijay Kumar | 3%upside $390 | Outperform Maintained | 2 May 2025 |
Needham Mike Matson | 17%upside $442 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about SYK published over the past 30 days
Positive
The Motley Fool
4 days ago
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough.
Negative
Morningstar
1 week ago
The 3 Most Overvalued Stocks Top Managers Are Selling in 2025
The best fund managers are scaling back in these expensive stocks this year. 00:00 Introduction 00:39 Netflix NFLX 01:23 Mastercard MA 02:07 Stryker SYK Susan Dziubinski: I'm Susan Dziubinski with Morningstar.
Positive
Zacks Investment Research
2 weeks ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Neutral
Zacks Investment Research
3 weeks ago
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Neutral
PRNewsWire
3 weeks ago
Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich.
Positive
Seeking Alpha
1 month ago
Baron Opportunity Fund Q1 2025 Top Contributors And Detractors
xAI Holdings led performance, driven by rapid AI innovation, Grok 3 launch, and the strategic acquisition of X, enhancing data access and integration. Spotify delivered strong results with margin expansion, robust user growth despite price hikes, and record free cash flow, positioning it as a long-term streaming leader. Nvidia, Tesla, and Broadcom detracted due to market skepticism and macro concerns, but we remain confident in their long-term AI-driven growth prospects.
Neutral
Seeking Alpha
1 month ago
Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)
Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.
Positive
The Motley Fool
1 month ago
Billionaire Terry Smith, "the English Warren Buffett," Has 31% of His Hedge Fund's Portfolio Invested in 3 Exceptional Stocks
If you read Fundsmith's Owner's Manual, the influence of Warren Buffett on Terry Smith's hedge fund is plainly obvious. Smith references the Oracle of Omaha's wisdom and Berkshire Hathaway's success no fewer than six times in the 17-page document.
Positive
Seeking Alpha
1 month ago
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.
Neutral
GlobeNewsWire
1 month ago
Stryker declares an $0.84 per share quarterly dividend
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better.
Charts implemented using Lightweight Charts™